Metabolic Research

Dulaglutide (Trulicity)

FDA-approved product existsWeight & metabolic
Not yet scored

BioHarmony verdict

Awaiting review

No BioHarmony report yet. It is queued for review; until then, rely on the status and sources below.

What is Dulaglutide (Trulicity)?

FDA-approved dulaglutide is marketed as Trulicity for improving glycemic control in adults and children 10 years and older with type 2 diabetes, with additional labeled cardiovascular-risk reduction in adults.

Dosing as published

Approved labelTRULICITY prescribing information for type 2 diabetes
PopulationAdults and pediatric patients covered by the approved TRULICITY indication
DoseThe adult starting dose is 0.75 mg once weekly and may be increased according to the label. Pediatric dosing starts at 0.75 mg once weekly and has a separate labeled maximum.
RouteSubcutaneous injection in the abdomen, thigh, or upper arm
FrequencyOnce weekly
DurationLong-term use within the approved indication
PreparationReady-to-use solution in a single-dose pen; no reconstitution.
Source: Dosage and Administration section 2; Dosage Forms and Strengths section 3

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

US approvalFDA-approved product exists
CompoundingFDA-approved product exists; compounded copies are not FDA approved
Last checked2026-07-13
Next review2026-10-11

Primary sources

  1. 6.5/10MOTS-cWorth tryingWeight & metabolicNot FDA approvedMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
  2. 6.2/10IpamorelinWorth tryingRecoveryNot FDA approvedIpamorelin is a selective growth-hormone secretagogue with strong receptor selectivity but almost no human efficacy data: its only completed human efficacy trial…
  3. 6.1/10TirzepatideWorth tryingWeight & metabolicFDA-approved product existsTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
  4. 6.0/10Semaglutide (GLP-1 Agonist)Worth tryingWeight & metabolicFDA-approved product existsSemaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 6.0-6.5/10 score holds…

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.